EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

22. How should clinics assess vial size, dosing instructions and beyond-use dates?

Dose Diligence research deskSection 01 · Page 22 of 34Last updated 17 Nov 2026

Assess the concentration, measuring device, instructions and usable period together. A large vial is not a saving if the planned use exceeds supported handling limits or increases dosing ambiguity.

FDA has reported dosing errors involving compounded injectable semaglutide, including confusion among milligrams, millilitres and syringe units. (fda.gov)

For a proposed compounded preparation, request pharmacist-approved documentation showing:

  • Concentration and prescribed dose in unambiguous terms.
  • Matching syringe or administration device.
  • Patient instructions and teach-back process.
  • Unopened beyond-use date and storage requirements.
  • Separate instructions after first puncture.
  • Expected unused quantity under the prescribed regimen.

An August 12, 2026 FDA letter reproduced by Arizona’s Board of Nursing discusses complaints about multi-dose GLP-1 vials whose contents exceed expected use within the customary 28-day post-puncture period. It distinguishes that concern from manufacturer-labelled instructions for approved products. (azbn.gov)

Do not create a longer use period in a spreadsheet to make a quote look economical. Resolve it with the dispensing pharmacist and clinical leadership.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  2. azbn.gov · Source 2 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
Section sources →